Clinical Trial Update: A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer; status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Carcinoma of the Prostate | Phase 2 | Status: UNKNOWN